Gland Pharma Limited
Sembol: GLAND.NS
NSE
1688.1
INRBugünkü piyasa fiyatı
42.3302
F/K Oranı
-1.6054
PEG Oranı
278.05B
MRK Kapağı
- 0.00%
DIV Verimi
Gland Pharma Limited (GLAND-NS) Finansal Tablolar
Bilanço
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 38362 | 32427.2 | 24465 | |||||||
balance-sheet.row.short-term-investments | 0 | 19273 | 29268.9 | 19546.8 | |||||||
balance-sheet.row.net-receivables | 0 | 8715.3 | 12514.7 | 12726.8 | |||||||
balance-sheet.row.inventory | 0 | 19453 | 11856.7 | 12751.7 | |||||||
balance-sheet.row.other-current-assets | 0 | 2477.8 | 1722.3 | 1292.9 | |||||||
balance-sheet.row.total-current-assets | 0 | 69008.1 | 58520.8 | 51236.4 | |||||||
balance-sheet.row.property-plant-equipment-net | 0 | 17361 | 17269 | 13244.4 | |||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.intangible-assets | 0 | 116.6 | 125.3 | 0 | |||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 116.6 | 125.3 | 0 | |||||||
balance-sheet.row.long-term-investments | 0 | -733.7 | 2000 | -19477.3 | |||||||
balance-sheet.row.tax-assets | 0 | 958.9 | -415.1 | 0 | |||||||
balance-sheet.row.other-non-current-assets | 0 | 1064.4 | 836.1 | 19957.3 | |||||||
balance-sheet.row.total-non-current-assets | 0 | 18767.3 | 19815.4 | 13724.4 | |||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.total-assets | 0 | 87775.4 | 78336.2 | 64960.8 | |||||||
balance-sheet.row.account-payables | 0 | 5873.5 | 4628.5 | 4007.3 | |||||||
balance-sheet.row.short-term-debt | 0 | 7.1 | 2.6 | 3 | |||||||
balance-sheet.row.tax-payables | 0 | 9.8 | 179.8 | 286.9 | |||||||
balance-sheet.row.long-term-debt-total | 0 | 37.4 | 44.8 | 47 | |||||||
Deferred Revenue Non Current | 0 | 49.9 | 55.5 | 56.7 | |||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||
balance-sheet.row.other-current-liab | 0 | 924.7 | 552.6 | 63.3 | |||||||
balance-sheet.row.total-non-current-liabilities | 0 | 896.8 | 939.8 | 803.1 | |||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.capital-lease-obligations | 0 | 6.3 | 8.1 | 9.3 | |||||||
balance-sheet.row.total-liab | 0 | 8188.1 | 6760 | 5928.4 | |||||||
balance-sheet.row.preferred-stock | 0 | 15.6 | 0 | 0 | |||||||
balance-sheet.row.common-stock | 0 | 164.7 | 164.3 | 163.6 | |||||||
balance-sheet.row.retained-earnings | 0 | 60153.9 | 52343.4 | 40226.8 | |||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | -15.6 | 114.5 | 240.9 | |||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 19268.6 | 18953.9 | 18401.1 | |||||||
balance-sheet.row.total-stockholders-equity | 0 | 79587.2 | 71576.2 | 59032.4 | |||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 87775.4 | 78336.2 | 64960.8 | |||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.total-equity | 0 | 79587.2 | 71576.2 | 59032.4 | |||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||
Total Investments | 0 | 18539.3 | 2000 | 69.5 | |||||||
balance-sheet.row.total-debt | 0 | 44.5 | 47.4 | 50 | |||||||
balance-sheet.row.net-debt | 0 | -19044.4 | -3110.8 | -4868.3 |
Nakit Akış Tablosu
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 10545.8 | 16185.5 | 13348.1 | |||||||
cash-flows.row.depreciation-and-amortization | 0 | 1467.4 | 1103 | 987.8 | |||||||
cash-flows.row.deferred-income-tax | 0 | 0 | -4143.8 | -3254 | |||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 46.2 | 155.3 | |||||||
cash-flows.row.change-in-working-capital | 0 | -4179.4 | -3930.8 | -4357.6 | |||||||
cash-flows.row.account-receivables | 0 | 1440 | -4195.7 | -602 | |||||||
cash-flows.row.inventory | 0 | -7596.3 | 895 | -5188.9 | |||||||
cash-flows.row.account-payables | 0 | 1209.8 | 658.5 | 1428.2 | |||||||
cash-flows.row.other-working-capital | 0 | 767.2 | -1288.6 | 5.1 | |||||||
cash-flows.row.other-non-cash-items | 0 | -4194.1 | -1352.4 | -830.4 | |||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -2231.2 | -5221.2 | -2287.8 | |||||||
cash-flows.row.acquisitions-net | 0 | -12705.6 | 6117.2 | 4.3 | |||||||
cash-flows.row.purchases-of-investments | 0 | -4699.8 | -16818.1 | -13575.9 | |||||||
cash-flows.row.sales-maturities-of-investments | 0 | 17405.4 | 10700.9 | -4.3 | |||||||
cash-flows.row.other-investing-activites | 0 | 14313.1 | -4805 | 623.7 | |||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 12081.9 | -10026.2 | -15240 | |||||||
cash-flows.row.debt-repayment | 0 | -1.1 | -1.4 | -8.9 | |||||||
cash-flows.row.common-stock-issued | 0 | 215 | 385.5 | 12418.1 | |||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.other-financing-activites | 0 | -64.7 | -35.2 | -24.6 | |||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 149.2 | 349 | 12384.6 | |||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 30 | 33.1 | 35.8 | |||||||
cash-flows.row.net-change-in-cash | 0 | 15900.8 | -1736.4 | 3229.7 | |||||||
cash-flows.row.cash-at-end-of-period | 0 | 19089 | 3188.2 | 4924.6 | |||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 3188.2 | 4924.6 | 1695 | |||||||
cash-flows.row.operating-cash-flow | 0 | 3639.7 | 7907.7 | 6049.3 | |||||||
cash-flows.row.capital-expenditure | 0 | -2231.2 | -5221.2 | -2287.8 | |||||||
cash-flows.row.free-cash-flow | 0 | 1408.5 | 2686.5 | 3761.5 |
Gelir Tablosu Satırı
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 36246 | 43841.4 | 34236.4 | |||||||
income-statement-row.row.cost-of-revenue | 0 | 16854.3 | 21092.2 | 14918.7 | |||||||
income-statement-row.row.gross-profit | 0 | 19391.7 | 22749.3 | 19317.6 | |||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||
income-statement-row.row.other-expenses | 0 | 2404.6 | 16 | 82.8 | |||||||
income-statement-row.row.operating-expenses | 0 | 10611.5 | 8745.5 | 7280.4 | |||||||
income-statement-row.row.cost-and-expenses | 0 | 27465.7 | 29837.7 | 22199.2 | |||||||
income-statement-row.row.interest-income | 0 | 1794.2 | 1386.5 | 859.5 | |||||||
income-statement-row.row.interest-expense | 0 | 74.5 | 34 | 29.1 | |||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||
income-statement-row.row.total-other-income-expensenet | 0 | 1701.4 | 2185.2 | 1313.7 | |||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||
income-statement-row.row.other-operating-expenses | 0 | 2404.6 | 16 | 82.8 | |||||||
income-statement-row.row.total-operating-expenses | 0 | 1701.4 | 2185.2 | 1313.7 | |||||||
income-statement-row.row.interest-expense | 0 | 74.5 | 34 | 29.1 | |||||||
income-statement-row.row.depreciation-and-amortization | 0 | 1467.4 | 1103 | 987.8 | |||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||
income-statement-row.row.operating-income | 0 | 8844.4 | 14000.3 | 12034.5 | |||||||
income-statement-row.row.income-before-tax | 0 | 10545.8 | 16185.5 | 13348.1 | |||||||
income-statement-row.row.income-tax-expense | 0 | 2735.4 | 4068.9 | 3378.5 | |||||||
income-statement-row.row.net-income | 0 | 7810.4 | 12116.6 | 9969.6 |
Sıkça Sorulan Sorular
Nedir Gland Pharma Limited (GLAND.NS) toplam varlıklar?
Gland Pharma Limited (GLAND.NS) toplam varlıklar 87775350000.000 şeklindedir.
İşletmenin yıllık geliri nedir?
Yıllık gelir N/A'dur.
Firma kâr marjı nedir?
Firma kar marjı 0.605'dir.
Şirket serbest nakit akışı nedir?
Serbest nakit akışı 35.155'dur.
İşletme net kar marjı nedir?
Net kâr marjı 0.134'dir.
Firma toplam geliri nedir?
Toplam gelir 0.189'dur.
Nedir Gland Pharma Limited (GLAND.NS) net kar (net gelir)?
Net kar (net gelir) 7810430000.000'dur.
Firmanın toplam borcu nedir?
Toplam borç 44530000.000'dir.
Faaliyet giderleri rakamı nedir?
İşletme giderleri 10611470000.000'dır.
Şirket nakit rakamı nedir?
İşletme içi nakit 0.000'tir.